Jeffrey Wade

Jeffrey L. Wade is president and chief financial officer of Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering transformative new medicines, having previously served in a series of finance, corporate development, administrative and legal executive roles since joining the company in 1999. He has played an instrumental role in completing securities offerings for Lexicon totaling more than $1 billion; completing the acquisition of Coelacanth Corporation that established the basis for the company’s small molecule drug discovery efforts; and negotiating collaborations and licenses involving more than $1 billionin committed funding to the company, including strategic alliances with Sanofi, Bristol-Myers Squibb, Genentech, Ipsen and Takeda. Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth, where his practice consisted primarily of corporate finance and securities transactions, mergers and acquisitions, and partnerships and alliances. He is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and BioHouston. Mr. Wade received his B.A. (Plan II) and J.D. from The University of Texas.